Galecto Biotech
PublicGalecto Biotech is now publicly traded
The data on this page reflects Galecto Biotech's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Oct 28, 2020
Last Round
Private Placement
Nov 10, 2025
Total Funding Raised
$527.9M
Company Overview
Galecto (NAS: GLTO) is a biotechnology company focused on developing therapeutics that target the biological processes underlying fibrosis and related diseases, including cancer.
Sector
Healthcare
AI Layer
Non-AI
Keywords
Galecto Biotech Comparables
Compare Galecto Biotech with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| ImmunoMet Therapeutics | 65% | |
| 株式会社抗体医学研究所 | 64% | |
| MetaNovas Biotech | 57% |
Galecto Biotech Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Private Placement | Nov 10, 2025 | ||||
| IPO | Oct 28, 2020 | ||||
| Series D | Sep 25, 2020 | ||||
| Series C | Oct 26, 2018 | ||||
| Series A | Oct 30, 2013 |
Galecto Biotech Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Andreessen Horowitz | Private Placement |
| Heartcore Capital | Seed, Series A, Series C, Series D |
| Soleus Capital | Series D |
| Janus Henderson Group | Series D, Private Placement |
| Balyasny Asset Management L.P. | Private Placement |
| RA Capital Management | Private Placement |
| TCG Crossover | Private Placement |
Galecto Biotech Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access